

# **EXHIBIT C**

1 UNITED STATES DISTRICT COURT  
2 FOR THE DISTRICT OF MASSACHUSETTS  
3 IN RE: PHARMACEUTICAL )  
4 INDUSTRY AVERAGE WHOLESALE ) MDL NO. 1456  
5 PRICE LITIGATION ) CIVIL ACTION:  
6 THIS DOCUMENT RELATES TO ) 01-CV-12257-PBS  
7 U.S. ex rel. Ven-A-Care of ) Judge Patti B. Saris  
8 the Florida Keys, Inc. v. )  
9 Abbott Laboratories Inc., ) Chief Magistrate Judge  
10 No. 07-CV-11618-PBS ) Marianne B. Bowler

11 HIGHLY CONFIDENTIAL  
12 CONTINUED VIDEOTAPED 30(b)(6) DEPOSITION OF  
13 JOHN M. LOCKWOOD, M.D.

14 Volume II  
15 (Taken by Defendant Abbott Laboratories Inc.)

16 April 24, 2009

17 9:44 a.m.

18 Suite 800

19 1420 Peachtree Street, N.E.

20 Atlanta, Georgia

21 Reported by: F. Renee Finkley, RPR, CRR, CLR,  
22 CCR-B-2289

1 it is. It says it's a product listing catalog and  
2 the date is here, and the cover says that it's  
3 AmerisourceBergen over-the-counter and, I guess,  
4 prescription drug price list.

5 Q. At any time did Ven-A-Care provide any  
6 information about the named Ery NDCs to the OIG?

7 MR. BREEN: You're including anybody in  
8 the OIG in that question?

9 THE WITNESS: I would say that in regards  
10 to the OIG, we started sending information to  
11 the OIG in, I think, July of 1999 regarding  
12 concerns about drugs that -- and oral drugs that  
13 if they had had accurate price reporting,  
14 meaning an accurate WAC price reported, a real  
15 WAC price, meaning the actual transaction WAC  
16 prices reported, that the FUL would have been a  
17 different number than what it was.

18 So we started interacting with the OIG on  
19 that subject or that topic, and it really  
20 culminated in, I think, my discovery in 2000  
21 that there was a similar problem with these Ery  
22 drugs. And when we went to talk about these

1 drugs as we were adding them to the Boston  
2 complaint, my recollection is the people in the  
3 room at that time included members of the  
4 Department of Justice and the OIG and a number  
5 of other government officials. So they were  
6 part of that meeting that occurred.

7 I think 1/18 or 1/19 of 2001 we did a  
8 Power Point that -- where we discussed other  
9 issues, but we discussed the Ery drugs that we  
10 were adding to the complaint within the  
11 following month, as I recall. I could check the  
12 date that we filed the first amended complaint  
13 in Boston that included the Ery drugs. But we  
14 discussed the drugs that were added at that time  
15 with the members of the OIG and DOJ.

16 And one of the factors that we discussed  
17 in particular was really a follow-up to our  
18 discussions about the FUL and drugs that, had  
19 they been accurately reported, it was part of  
20 that whole thing that we were doing and the OIG  
21 was present.

22 Q. (By Mr. Berlin) Who from the OIG was